Home ›
Lymphoma Trials ›
NCT06730542
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
Trial Details
NCT ID NCT06730542
Phase PHASE1
Sponsor Juan P. Alderuccio, MD
Status RECRUITING
Cancer Type Lymphoma
Interventions Zanubrutinib Methotrexate Polatuzumab Vedotin Rituximab Cyclophosphamide Doxorubicin
Locations (sample) Miami, Florida, United States|25.77427,-80.19366
Key Eligibility Criteria
Men and women ≥ 18 years of age on the day of signing the informed consent form (or the legal age of consent in the jurisdiction in which the study… Patients must have histologic confirmation of large B-cell lymphoma (LBCL) defined by the World Health Organization (WHO) classification. All LBCL … Baseline 18-fluorodeoxyglucose (FDG)-positron emission tomography scan/computed tomography (PET/CT) must demonstrate FDG avid lesions compatible wi… Presence of systemic and CNS involvement (brain, cerebellum, brainstem, meninges, cranial nerves, eyes, spinal cord, or a combination of these) at …
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →